martes, 18 de octubre de 2016

Lot Release (Biologics) > Influenza Virus Vaccine for the 2016-2017 Season

Lot Release (Biologics) > Influenza Virus Vaccine for the 2016-2017 Season

New FDA Logo Blue

This page has been updated recently.

Updated: 10/18/2016


FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on March 4, 2016, to select the influenza viruses for the composition of the influenza vaccine for the 2016-2017 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2015-2016 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2016-2017 influenza season contain the following:
  • an A/California/7/2009 (H1N1)-like virus;
  • an A/Hong Kong /4801/2014 (H3N2)-like virus
  • a B/Brisbane/60/2008-like virus (B/Victoria lineage).
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
  • a B/Phuket/3073/2013-like virus (B/Yamagata lineage)